ライフサイエンスコーパス: tumor-specific

1 lls, suggesting that responding cells may be tumor specific.

2 use on-target toxicities if the POIs are not tumor-specific.

3 cell death both in vitro and in vivo through tumor-specific (1) O2 generation and subsequent ROS medi

4 oncology involves identifying and targeting tumor-specific aberrations resulting from causative SGAs

5 s) fail to exclude reactive subsets, whereas tumor-specific abnormalities are subtle and inconsistent

6 particles demonstrated orthotopic pancreatic tumor specific accumulation compared to liver or kidney

7 promoter deposition correlated strongly with tumor-specific activation and repression of transcriptio

8 ta-24-RGD, Delta-24-RGDOX exhibited superior tumor-specific activation of lymphocytes and proliferati

9 netic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-assoc

10 erapy because of their capacity to stimulate tumor-specific activity in vivo.

11 oncogene addiction in cancer and the role of tumor-specific adaptations conferring therapeutic resist

12 nanocarriers and/or affinity targeting with tumor-specific affinity ligands, such as tumor homing pe

13 The majority of tumor-specific alterations in ovarian cancers were prese

14 argets were identified as both ancestral and tumor-specific alterations.

15 emotherapy (nATC) delivery strategy in which tumor specific and clinically relevant antibodies (ritux

16 of cell surface antigens classified as truly tumor specific and is well suited for therapy developmen

17 Tumor-specific and cell-autonomous activation of the tum

18 The systemic tumor-specific and cell-mediated immunotherapy response

19 tic effect of entolimod and establishment of tumor-specific and durable immune memory.

20 ikely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibil

21 dent suppression by Tregs and, thus, enhance tumor-specific and, likely, virus-specific immunity.

22 fusion partners, most notably EWSR1, are not tumor specific (and may, in fact, also be found in benig

23 er vaccination, resulting in an efficacious, tumor-specific, and long-lasting therapeutic effect.

24 Therapeutic concepts exploiting tumor-specific antibodies are often established in pre-c

25 with intratumoral injection of an IL2-linked tumor-specific antibody (termed here an immunocytokine),

26 CD47 blockade alone or in combination with a tumor-specific antibody fails to generate antitumor immu

27 Re-activation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critic

28 ), also known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

29 te-associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield

30 otherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC).

31 on of low-abundance MHC I peptides including tumor-specific antigens (TSAs) and minor histocompatibil

32 ow that host T cells properly primed against tumor-specific antigens after conventional treatment, wh

33 The high affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies

34 ese findings highlight an important class of tumor-specific antigens and have implications for target

35 olid tumors is hampered by the lack of truly tumor-specific antigens and poor control over T cell act

36 CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients

37 read occurrence and strong immunogenicity of tumor-specific antigens derived from shared frameshift m

38 uous' repair mechanisms and the induction of tumor-specific antigens that can be targeted.

39 dendritic cells and prevents presentation of tumor-specific antigens to other immune cells.

40 on to the type as well as level of expressed tumor-specific antigens, thereby presenting methods for

41 remains limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppressi

42 on that does not depend on identification of tumor-specific antigens.

43 fector T cells, marked tumor regression, and tumor-specific antitumor immune memory.

44 hermore, we demonstrated evidence of durable tumor-specific antitumor immunity.

45 itivity, and the mechanism of statin-induced tumor-specific apoptosis remains unclear.

46 Cs, and that TRAIL-expressing hADSCs induced tumor-specific apoptosis.

47 DEGs) in the proximity of the human prostate tumor-specific AR binding sites.

48 SPECT biodistribution data further validated tumor-specific binding.

49 stoma models and thus enhance the release of tumor-specific biomarkers into the bloodstream.

50 Our hypothesis states that tumor-specific biomarkers such as entropy should be corr

51 These tumor-specific blood vessels are characterized by a deve

52 L1 targeting relies upon the reactivation of tumor-specific but functionally impaired PD-1(+) T cells

53 ition constants and high selectivity for the tumor-specific CAIX over cytosolic isoform CAII.

54 rs induce sufficient host T cells expressing tumor-specific CARs or virus-specific TCRs to cause dise

55 We report a tumor-specific causal inference (TCI) framework, which e

56 kine-induced natural killer cells to achieve tumor-specific CD22 targeting.

57 ffect that results from enhanced function of tumor-specific CD4 T cells, and ultimately requires tumo

58 apy results in enhanced effector function of tumor-specific CD4 T cells, mainly through enhanced prod

59 tioning allowed adoptively transferred naive tumor-specific CD4+ T cells to undergo effector differen

60 enic death of tumor cells, increase systemic tumor-specific CD8 + T cells, repolarize tumor-associate

61 Thus, sepsis has the capacity to improve tumor-specific CD8 T cell responses, leading to better c

62 1 and LAG-3 (denoted PD-1(hi)) that define a tumor-specific CD8 T cell subset that retain some functi

63 cells display a gene signature comparable to tumor-specific CD8 T cells in a fixed state of dysfuncti

64 T with a pathogen, we genetically engineered tumor-specific CD8 T cells in vitro with a second T-cell

65 In this study, we show in contrast to tumor-specific CD8 T cells that pathogen-specific primar

66 eckpoint inhibitors, with anti-CD40 to yield tumor-specific CD8 T cells, and with anticancer monoclon

67 Tumor-specific CD8(+) cytotoxic T lymphocytes (CTLs) pla

68 the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiati

69 rammed death-1 (PD-1) and its ligands hamper tumor-specific CD8(+) T cell (TCD8) responses, and PD-1-

70 n enhanced cross-priming capacity of DCs and tumor-specific CD8(+) T cell activation.

71 , explaining their reduced ability to induce tumor-specific CD8(+) T cell priming.

72 -presenting cells and activate them to prime tumor-specific CD8(+) T cell responses.

73 , we compared genome-wide mRNA expression of tumor-specific CD8(+) T cells from the tumor and periphe

74 ld alter the CpG-mediated differentiation of tumor-specific CD8(+) T cells into CD127(low)KLRG1(high)

75 However, the role of cDC1s in expansion of tumor-specific CD8(+) T cells remains unclear.

76 antitumor efficacy of adoptively transferred tumor-specific CD8(+) T cells were abrogated in Batf3(-/

77 ated with increases in the systemic level of tumor-specific CD8(+) T cells, and an increased ratio of

78 ntigen presentation follows, which generates tumor-specific CD8(+) T cells, conferring prolonged tumo

79 ma signaling, led to impaired recognition by tumor-specific CD8(+) T cells.

80 , increasing the quantity and the quality of tumor-specific CD8(+) T cells.

81 depleted CCR2(+) Treg, enhancing priming of tumor-specific CD8(+) T cells.

82 tact antigens to the lymph nodes and priming tumor-specific CD8(+) T cells.

83 t dendritic cells (DC) could further enhance tumor-specific CD8(+) T-cell polyfunctionality in vivo w

84 nology, the authors isolate and characterize tumor-specific CD8+ and CD4+ T cells in murine tumor mod

85 y and that this regimen triggered a systemic tumor-specific CD8+ T cell response.

86 itical for the activation and maintenance of tumor-specific CD8+ T cells.

87 SF35 in subcutaneous B16 melanomas generates tumor-specific, CD8(+) T cells that express PD-1 and sup

88 Notably, JA induced significant tumor-specific cell death and a significant increase in

89 d NAD metabolism, which can be exploited for tumor-specific cell killing.

90 er the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulati

91 These findings identify ALPP2 as a true tumor-specific cell surface antigen whose tissue specifi

92 Identification of tumor-specific cell surface antigens has proven challeng

93 omas express a functionally active and truly tumor-specific cell-surface product, the variable region

94 Adoptive transfer of these tumor-specific cells significantly suppresses tumor grow

95 a comprehensive cell atlas and characterize tumor-specific cells.

96 Our work provides unbiased insights into tumor-specific cellular identities in a whole tissue env

97 n this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentat

98 our study will need further interrogation in tumor-specific cohorts.

99 rix (ECM) is degraded and substituted with a tumor-specific collagen-rich ECM.

100 In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromo

101 We developed a novel tumor-specific computational framework that finds the li

102 nfrared labeled ErbB2 peptide that generates tumor-specific contrast in human xenograft breast tumors

103 PKCiota gene PRKCI is targeted for frequent tumor-specific copy number gain (CNG) in both lung squam

104 E-cadherin-Fc of CD103 integrin expressed on tumor-specific CTL clones promotes phosphorylation of Px

105 tumor-infiltrating lymphocytes and CD103(+) tumor-specific CTL clones.

106 t cancer requires simultaneous generation of tumor-specific CTLs and curtailment of tumor immunosuppr

107 noma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer.

108 date have focused on transfer of autologous tumor-specific cytotoxic CD8(+) T cells; however, the po

109 osuppression, which inhibits infiltration of tumor-specific cytotoxic CD8+ T cells.

110 ated distant tumors by generating a systemic tumor-specific cytotoxic T cell response.

111 lammation and, eventually, the activation of tumor-specific cytotoxic T cells, their recruitment into

112 virus (MYXV) that shows high efficiency for tumor-specific cytotoxicity in small-cell lung cancer (S

113 in cancer and healthy cells and explain the tumor-specific cytotoxicity of V-ATPase inhibition.

114 Tumor-specific ddPCR was developed to measure the corres

115 ivery of nanoparticles, we examined enhanced tumor-specific delivery of amphiphile-CpG, an albumin-bi

116 The success of radiotherapy relies on tumor-specific delivery of radiosensitizers to attenuate

117 Taken together, we identify tumor-specific dependence on NOX2-driven mitochondrial t

118 , leading to dysfunctional gene splicing and tumor-specific dependencies.

119 Furthermore, tumor-specific disruption of Notch signaling may overcom

120 nefits beyond tumoricidal effects to harness tumor-specific, durable, and systemic antitumor immunity

121 d by a lack of cell surface markers defining tumor-specific dysfunctional TILs, and PD-1 alone is not

122 f these multipronged approaches is to expand tumor-specific effector T-cells, break checkpoint recept

123 Tumor-specific elucidation of physical and functional on

124 We leverage gains in tumor-specific enhancer activity, coupled with allele-bi

125 recruited by the EWS-FLI1 fusion protein to tumor-specific enhancers and contributes to target gene

126 Tumor-specific enhancers and superenhancers that are elu

127 -positive breast cancer risk, (ii) exploring tumor-specific enhancers in selective MYC dysregulation

128 uggests that normal ER signaling is lost and tumor-specific ER signaling is gained during breast tumo

129 hanges in normal and WM development captured tumor-specific events, highlighting a selective reprogra

130 odulatory gene circuit platform that enables tumor-specific expression of immunostimulators, which co

131 Expression of SPZ1 exhibited a tumor-specific expression pattern and a high correlation

132 sicle secretion, suggesting that identifying tumor-specific extracellular vesicle proteins in plasma

133 led to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence

134 ormal B cells from the same patient revealed tumor-specific features.

135 Recommendations On the basis of tumor-specific findings and competing risks of mortality

136 We identified tumor-specific frameshifts encoding multiple epitopes th

137 ferential histone enrichment associated with tumor-specific gene expression variation, sites of HPV i

138 tart site (TSS) with methylation-associated, tumor-specific gene silencing.

139 Targeted cancer therapeutics aim to exploit tumor-specific, genetic vulnerabilities specifically aff

140 Tumor-specific genomic aberrations are routinely determi

141 Tumor-specific genomic alterations allow systematic iden

142 Tumor-specific glycosylation changes are an attractive t

143 ed for antibody fragments that recognize the tumor-specific glycosylation present on glycoforms of pe

144 Recent studies suggest that non-canonical tumor-specific HLA peptides derived from annotated non-c

145 r progression, migration, and suppression of tumor-specific host immune responses.

146 rization) in glioma and the analysis of this tumor-specific HuR protein multimerization in clinical b

147 Importantly, while the frequency of tumor-specific IFN-gamma producing CD8(+) T-cells was si

148 resulted in a significantly higher number of tumor-specific IFN-gamma-secreting immune cells compared

149 RR-S-Ac3 ManNAz is promising for research in tumor-specific imaging or drug delivery.

150 ieve selective background quenching and high tumor-specific imaging.

151 ese agents are required to be biocompatible, tumor-specific, imaging distinguishable and therapeutica

152 s in PDAC possibly due to better delivery of tumor specific immune cells.

153 We further identify tumor-specific immune clusters with phenotypic character

154 cordingly, BCG-induced tumor elimination and tumor-specific immune memory require tumor cell expressi

155 kdown not only kills CSCs but also elicits a tumor-specific immune response that converts dying CSCs

156 block immune regulatory pathways to enhance tumor-specific immune responses for the treatment of can

157 for lymphoma cells and its ability to induce tumor-specific immune responses, 11 has the potential to

158 linking activated T cells to suppression of tumor-specific immune responses, providing a conceptual

159 mor-derived heat shock proteins can generate tumor-specific immune responses.

160 cell death (ICD) is a way of reengaging the tumor-specific immune system.

161 diting, decreased neoantigen expression, and tumor-specific immune tolerance.

162 ion, and infiltration, resulting in enhanced tumor-specific immune-mediated tumor regressions in prim

163 MV (MCMV) delayed tumor growth and activated tumor-specific immunity although the mechanism was uncle

164 elimination depends on bacteria-specific or tumor-specific immunity is unknown.

165 In contrast, BCG stimulates long-term tumor-specific immunity that primarily depends on CD4 T

166 affects both the innate and adaptive arms of tumor-specific immunity.

167 ), eliminate various large tumors and induce tumor-specific immunity.

168 tance to anti-PD-L1 therapy, and establishes tumor-specific immunological memory.

169 To garner an insight into tumor-specific immunomodulatory targets, we analyzed 94

170 lls/mul and including 13 cases (23%) lacking tumor-specific immunophenotypic abnormalities.

171 ified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

172 An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the

173 leled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets.

174 photoactivation could be shown by using the tumor-specific, integrin-targeting (90)Y-DOTA-RGD and th

175 next-generation RNA sequencing have revealed tumor-specific isoforms associated with these alteration

176 ecapitulating normal epidermal states, and a tumor-specific keratinocyte (TSK) population unique to c

177 ubstantial capabilities of proliferation and tumor-specific killing.

178 mprised of fluorescein linked to a different tumor-specific ligand, to bridge between an antifluoresc

179 inally, we recover the complete sequences of tumor-specific LINE-1 insertions and their retrotranspos

180 tion of the extrinsic apoptosis pathway in a tumor-specific manner by binding to and trimerizing its

181 owed that lncRNAs were deregulated in a more tumor-specific manner.

182 ver therapeutic payloads to macrophages in a tumor-specific manner.

183 hed tumors in most animals associated with a tumor-specific memory T-cell response.

184 s who underwent total mesorectal excision or tumor-specific mesorectal excision for rectal cancer bet

185 findings reveal a previously unappreciated, tumor-specific metabolic pathway hijacked from one of th

186 It is the key technique for developing tumor-specific metabolic precursors that can generate un

187 loss reduced activation of Wnt/beta-catenin, tumor-specific metabolism and inflammation, significantl

188 The tumor-specific methylation of ANKDD1A indicates that it

189 We concluded that entropy is a tumor-specific metric only if confounding factors are co

190 Genes can exhibit lymphoma subtype- or tumor-specific MHC-I regulation, and a majority of prima

191 oma cells (PDACs), drives the formation of a tumor-specific microenvironment.

192 e CD47-SIRPalpha interaction synergizes with tumor-specific monoclonal antibodies to eliminate human

193 Detection of lymphocytes that target tumor-specific mutant neoantigens--derived from products

194 (HTS) has been used successfully to discover tumor-specific mutant peptides (neoantigens) from somati

195 recognized as an important source generating tumor-specific mutant peptides (neoantigens).

196 Tumor-specific mutant peptides can be detected by the im

197 d by considering both germline genotypes and tumor specific mutations and expression profiles related

198 However, it is also important to identify tumor specific mutations that may determine response to

199 Tumor-specific mutations can generate neoantigens that d

200 fy hundreds to thousands of cells containing tumor-specific mutations in each case, and use the resul

201 cancer and tested their ability to recognize tumor-specific mutations.

202 ponse to personalized neoantigens encoded by tumor-specific mutations.

203 FSPs are tumor-specific neoantigens shared across patients with M

204 to higher frequency of somatic mutations and tumor-specific neoantigens.

205 satellite repeats and the potential for high tumor specific neoepitope levels.

206 indings suggest that despite the presence of tumor specific neoepitopes, T cell activation is activel

207 ate identification of hundreds of shared and tumor-specific non-canonical HLA peptides, including an

208 ll responses, providing a potent, individual tumor-specific oncolytic immunotherapy for cancer patien

209 ment, with a special emphasis on the role of tumor-specific oncometabolites.

210 data, network models can identify common or tumor specific pathway-level changes.

211 We observe patient-specific as well as tumor-specific patterns, including accurate prediction o

212 rt hairpin RNA (shRNA) adjuvants, as well as tumor-specific peptide neoantigens into antigen presenti

213 also the antitumor therapeutic activity of a tumor-specific peptide vaccine.

214 ytic adenovirus coated with MHC-I-restricted tumor-specific peptides and developed it further by intr

215 eptiCRAd containing both tetanus toxoid- and tumor-specific peptides.

216 onstruct the altered signaling pathways from tumor-specific phosphoproteomic data and known protein-p

217 s that was used to generate highly efficient tumor-specific probes.

218 r types of cancers by using their respective tumor-specific promoters.

219 mputational modeling can be used to identify tumor-specific properties that influence the response to

220 cruitment rate and tumor proliferation rate (tumor-specific properties) have large impacts on therapy

221 This investigation tests the feasibility of tumor-specific prostate brachytherapy achievable with Yb

222 ovide strong evidence for the feasibility of tumor-specific prostate brachytherapy with Yb-169 and gG

223 i-idiotypic mask and cleavage of the mask by tumor-specific proteases can be applied to enhance speci

224 lop a network-based strategy for identifying tumor specific proteins and pathways that were predicted

225 Here, the authors develop a tumor-specific quantum dot system that permits in vivo c

226 n receptors (CARs) have been used to enhance tumor-specific recognition by effector lymphocytes.

227 nd pending therapeutic approaches leveraging tumor-specific replication stress as a target, in additi

228 ate personalized ICBT strategies that target tumor-specific resistance mechanisms.

229 1 signaling potentiates epitope spreading in tumor-specific responses, a finding with clear implicati

230 ormal tissues holds the potential to develop tumor-specific/selective PROTACs.

231 s with a special focus on the development of tumor-specific/selective PROTACs.

232 estigated the ability of CD4 cells to target tumor-specific self-antigens modified by citrullination,

233 e of FIP family members, such as FIP1C, in a tumor-specific setting remains elusive.

234 of-heterozygosity (the first three also in a tumor-specific setting).

235 The tumor-specific shift to transcriptional repression assoc

236 enches excess quantum dots, leaving a highly tumor-specific signal provided by the intact quantum dot

237 e background quenching to gain exceptionally tumor-specific signals.

238 Nonetheless, tumor-specific signatures both in protein expression and

239 teomic and DNA methylation analyses revealed tumor-specific signatures linked to the evolutionary con

240 ch, however, is constrained by the rarity of tumor-specific single antigens.

241 table system has been developed that enables tumor-specific singlet oxygen ((1) O2 ) generation for c

242 Tumor-specific splicing alterations are created by mutat

243 on to distinguish between environmental- and tumor-specific STAT3 activities in gene expression studi

244 a dominant role at primary pancreatic sites, tumor-specific STAT3 seemed dominant at metastatic sites

245 lysis of CD4(+) T cells demonstrates several tumor-specific states, including multiple distinct state

246 urthermore, it should preferably not rely on tumor-specific surface markers, as these are only availa

247 atic tumor cells that express high levels of tumor-specific surface proteins and are composed of high

248 antitumor response was partially mediated by tumor-specific T cell immunity and immunological memory.

249 Peripheral tumor-specific T cell responses against main SCC-derived

250 Tumor-specific T cell responses are strongly impaired in

251 e hypothesized that functional impairment of tumor-specific T cell responses due to calcineurin inhib

252 ING-activating nanovaccine to boost systemic tumor-specific T cell responses in multiple tumor models

253 ant patients showed lower IT infiltrates and tumor-specific T cell responses than NoKT-SCC, and intra

254 nt increase in FOXP3 + Treg cell numbers and tumor-specific T cell responses were observed, reaching

255 Tumor-specific T cell responses were significantly lower

256 an in situ vaccination approach to activate tumor-specific T cell responses.

257 generation of ICOSL(+)B cells, which enhance tumor-specific T cell responses.

258 Combination treatment induced deletion of tumor-specific T cells and altered the T cell repertoire

259 mulation enhanced the number and function of tumor-specific T cells and, in long-term settings, reduc

260 timately increase the frequency of activated tumor-specific T cells are currently being explored.

261 The main target of tumor-specific T cells are neoantigens arising from muta

262 Adoptive cell therapy (ACT) with tumor-specific T cells can mediate cancer regression.

263 Activated tumor-specific T cells expressed higher amounts of inter

264 Optimal ex vivo expansion protocols of tumor-specific T cells followed by adoptive cell therapy

265 limited, in part due to the low frequency of tumor-specific T cells in the tumor microenvironment (TM

266 These results demonstrate that pre-existing tumor-specific T cells may have limited reinvigoration c

267 Metabolic reprogramming of tumor-specific T cells through enforced expression of AC

268 mportantly, IL-1beta enhanced the ability of tumor-specific T cells to trigger the regression of larg

269 In mice, transfer of tumor-specific T cells with deletion of P2rx7 significan

270 owed the rapid production of high numbers of tumor-specific T cells, with optimal TCR expression and

271 genesis, induced by chronic Akt signaling in tumor-specific T cells.

272 gies to prevent and/or reverse senescence in tumor-specific T cells.

273 ', may promote the development of long-lived tumor-specific T(mem) that are essential for durable ant

274 er with others, have previously demonstrated tumor-specific T-cell dysfunction in the allogeneic envi

275 However, identifying tumor-specific T-cell epitopes is a major challenge.

276 CD5-2 administration also enhanced tumor-specific T-cell infiltration and spatially redistr

277 or-draining lymph nodes induce activation of tumor-specific T-lymphocyte responses that can result in

278 ing using near infrared (NIR) dyes tagged to tumor specific target will benefit such developments.

279 oing; however, the mechanistic rationale for tumor-specific targeting of immune checkpoints is elusiv

280 f the main difficulties lies in a paucity of tumor-specific targets that can serve as CAR recognition

281 beta genes, followed by the introduction of tumor-specific TCR genes, and that proved safer and more

282 owed by the transfer of genes encoding for a tumor-specific TCR.

283 A-A2 ligands, as well as structures of three tumor-specific TCRs bound to p53R175H-HLA-A2.

284 patient with melanoma and identified several tumor-specific TCRs, which, after expression in primary

285 Therapeutic reactivation of tumor-specific TEs may synergize with immunotherapy by i

286 reported with IFNgamma-producing Th1 cells, tumor-specific Th2 cells have been largely neglected for

287 power of single-cell multi-omics to discover tumor-specific therapeutic targets and mediators of tiss

288 e of mutations that drive cancer will reveal tumor-specific therapeutic vulnerabilities.

289 Based on the unique TME for achieving tumor-specific therapy, here a novel concept of photothe

290 ndrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evide

291 Fully-human and tumor-specific, these antibodies are candidates for furt

292 paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs

293 PD-1 allows identification and isolation of tumor-specific TILs without previous knowledge of their

294 ecific PET/CT tracers, such as (18)F-NaF, or tumor-specific tracers, such as (18)F-FDG, although thes

295 Our approach for mapping tumor-specific transcription factor binding in vivo base

296 herapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventi

297 y to engineer a polymersome nanoreactor with tumor-specific tunable membrane permeability to load bot

298 mechanisms behind the observed increased and tumor specific uptake are not fully elucidated, it is de

299 ion of a PI3Kdelta-specific inhibitor with a tumor-specific vaccine decreased numbers of suppressive

300 intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associ